Yearly Archives: 2025
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.
New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation
Salt Lake City, UT –Wednesday November, 5th 2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and […]
Owlet Partners with Rhapsody to Connect Remote Baby Monitoring Data to EHRs
Collaboration bridges home and hospital, creating a secure pathway for pediatric insights to be managed and shared.
J3 Bioscience Announces Collaboration to Study LIV-Ring VR101 for Cancer-Therapy–Related Vaginal Dryness
Investigator-Initiated, grant-supported pilot study evaluating a novel non-prescription therapy for cancer-related vaginal dryness.
2025 BioUtah Life Sciences Awards Presented at the Mayer Brown Utah Life Sciences Summit
BioUtah will honor outstanding leaders in Utah’s life sciences community with five awards recognizing contributions to the industry.
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 months
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx’s existing and future AI initiatives
Health Insurance Costs 2026: Steep Increases Ahead for Employers, Including Life Sciences
Health insurance costs are projected to rise sharply in 2026
Co-Diagnostics Forms New AI Business Unit and Expands Global Footprint with CoMira Diagnostics
Co-Diagnostics Forms New AI Business Unit and Expands Global Footprint with CoMira Diagnostics
Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark
Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation.
